Astera Labs (ALAB) Stock Jumps 10% on RBC’s $250 Price Target Upgrade

Key Takeaways

• RBC Capital increased Astera Labs (ALAB) price target to $250 from $225, maintaining Outperform rating
• The optimistic outlook hinges on Trainium3-driven Scorpio-X switch sales beginning in Q3 2026
• RBC anticipates Scorpio switch sales escalating from $130M in 2025 to $390M in 2026
• UBS launched coverage with a Neutral stance and $180 price target, warning of switching sector competition
• ALAB delivered Q4 2025 EPS of $0.58, surpassing $0.51 consensus, while revenue climbed 92% annually to $270.6M

Astera Labs received attention from two major Wall Street firms on Monday, though their perspectives diverged significantly.

Astera Labs, Inc. Common Stock, ALAB

RBC Capital elevated its price objective for Astera Labs to $250 from the previous $225, maintaining an Outperform stance. Shares traded near $175.80 during the session, marking approximately 10% gains.

RBC’s optimistic thesis revolves around Scorpio-X, Astera’s advanced switch technology. The investment bank anticipates Trainium3-associated Scorpio-X revenue streams to materialize in Q3 2026, creating additional monetization opportunities per XPU.

The firm’s revenue forecasts for Scorpio switches show dramatic expansion: from $130 million in 2025 to $390 million in 2026 — essentially tripling within twelve months.

RBC’s updated $250 price objective reflects 74 times their calendar 2027 EPS forecast of $3.37. The previous target employed a 67x multiplier. RBC justified the expanded multiple by citing numerous product launches, substantial market opportunity, anticipated 40–50% revenue expansion, and gross margins exceeding 70%.

Astera’s current gross margin stands at 75.69%, accompanied by 115% revenue growth over the trailing twelve months.

UBS Adopts More Cautious Perspective

UBS also initiated coverage on ALAB Monday, but settled on a Neutral rating with a $180 objective — marginally above trading levels.

Analyst Natalia Winkler recognized the company’s established presence in AI networking infrastructure developed over five years, highlighting solid execution in retimer technology and customer diversification beyond AWS. Astera introduced retimer solutions in 2019 and has subsequently expanded adoption across multiple hyperscale operators.

UBS forecasts 2027 revenues 4% higher than consensus estimates, supported by retimers and the PCIe/UA Link switch portfolio. However, for 2028, UBS projects 3% below consensus, citing intensifying competition in the switching segment as a challenge.

Valuation concerns drive UBS’s cautious stance. Astera commands a high-40s 2027 P/E ratio, substantially above AI networking sector peers. The firm indicated superior risk-reward opportunities exist elsewhere in networking.

Recent Earnings Support Growth Narrative

Both analyst views follow impressive quarterly performance. Astera delivered Q4 2025 EPS of $0.58, exceeding the $0.51 consensus estimate by nearly 14%.

Quarterly revenue reached $270.6 million, representing 92% year-over-year growth.

According to InvestingPro data, twelve analysts have increased earnings projections for the forthcoming period.

The equity has generated 223% returns over the past year. Despite this substantial appreciation, ALAB’s PEG ratio of 0.47 indicates valuation may remain reasonable relative to growth — even with a headline P/E of 143.

RBC’s $250 objective suggests approximately 42% upside potential from present levels. UBS’s $180 target leaves minimal appreciation opportunity from current pricing.

The post Astera Labs (ALAB) Stock Jumps 10% on RBC’s $250 Price Target Upgrade appeared first on Blockonomi.